{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "interpro:IPR007702",
      "entity_text" : "Janus",
      "entity_type" : "family"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:O60674",
      "entity_text" : "JAK2",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "The purpose of our analysis was to explore the relationship between pain and fatigue with daily activity and work productivity, in patients from a randomized, double-blind, phase 3 clinical trial of baricitinib, an oral, selective inhibitor of Janus kinase (JAK) 1 and JAK2 [XREF_BIBR].",
  "reading_complete" : "2020-07-28T18:29:05Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T18:26:49Z",
  "trigger" : "inhibitor",
  "evidence" : [ "inhibitor of Janus kinase (JAK)1 and JAK2" ],
  "pmc_id" : "6702585",
  "score" : 0
}